Mathieu C, et al. - The efficacy and safety of fast-acting insulin aspart (faster aspart) with conventional insulin aspart (IAsp) were compared among adults with type 1 diabetes (T1D). Significantly improved glycaemic control was noted with faster aspart vs IAsp at 52 weeks, consistent with the 26-week study findings. In subjects with T1D, achieving an insulin profile closer to physiological insulin secretion with faster aspart translated into lower postprandial plasma glucose (PPG) and HbA_1c levels compared with IAsp.